Here, we present the results of meta-analysis and clinical trials reported so far with regard to the incidence of ILD when there is: (1) EGFR-TKI monotherapy, (2) a combination of EGFR-TKIs and other chemotherapeutic agents, and (3) a combination of EGFR-TKIs and immune checkpoint inhibitors (ICIs). The gene discussed is EGFR; the disease is interstitial lung disease.